Saturday 17 October 2026
Export LFWD’s income statement to Excel — free account
Lifeward Ltd.
LFWD Healthcare Medical Devices
Lifeward Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $22.0 million, down 14.1% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 40.8% and free cash flow fell 52.8%, each against the same quarter a year earlier.
6.00
0.06
−0.99%
Follow LFWD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.47 | 0.36 | 0.51 | 0.98 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.97) | (2.26) | (2.91) | (3.57) | |
P/B ratio |
0.89 | 0.96 | 1.70 | 1.75 | |
Price to Tangible BV |
1.42 | 2.20 | 6.95 | 3.05 | |
EV/Sales |
0.46 | 0.42 | 0.45 | 1.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.66) | (0.55) | (0.62) | (1.36) | |
EV/FCF |
(0.65) | (0.55) | (0.62) | (1.36) | |
Quick Ratio |
0.92 | 0.71 | 1.61 | 1.55 | |
Current Ratio |
1.92 | 1.31 | 2.40 | 2.33 | |
Net Debt/EBITDA |
0.72 | (0.08) | 0.95 | 0.25 | |
Debt/Assets |
0.00% | 12.24% | 21.77% | 24.33% | |
Debt/Equity |
0.00 | 0.33 | 1.16 | 0.70 | |
Asset Turnover |
0.71 | 0.83 | 0.67 | 0.71 | |
Operating CF/Net income |
1.21 | 0.66 | 0.34 | 0.52 | |
Capex/Depreciation |
0.00 | (0.15) | 0.00 | (0.02) | |
Research and Development Expense of Revenue |
11.64% | 16.59% | 148.99% | 26.48% | |
Selling, General and Administrative Expense of Revenue |
82.74% | 105.55% | 148.76% | 77.11% | |
Intangible Assets out of Total Assets |
0.21 | 0.21 | 0.14 | 0.15 | |
Share Based Compensation of Revenue |
2.81% | 3.29% | 4.51% | 3.96% | |
Graham Net Nets |
0.61 | 0.16 | (0.15) | 0.15 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(417.49%) | (267.14%) | (296.59%) | (219.60%) | |
Free Cash Flow Yield |
(152.00%) | (209.63%) | (140.66%) | (79.79%) | |
Revenue per Share |
4.64 | 4.38 | 2.44 | 2.37 | |
Operating CF per Share |
(2.88) | (3.06) | (2.28) | (2.15) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.88) | (3.07) | (2.28) | (2.15) | |
Cash per Share |
1.64 | 2.07 | 7.10 | 3.38 | |
Shareholders Equity per Share |
9.56 | 7.24 | 3.91 | 4.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.56 | 7.24 | 3.91 | 4.37 | |
Free Cash Flow |
(3.84) | (3.57) | (3.67) | (6.01) | |
Working Capital |
8.29 | 3.77 | 14.92 | 14.79 | |
Capital Expenditures |
0.00 | (0.01) | — | (0.01) | |
Net Current Asset Value |
6.93 | 1.32 | (1.57) | 3.16 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.98 | 6.07 | 5.41 | 6.86 | |
Average Payables |
5.12 | 5.31 | 5.42 | 6.12 | |
Average Inventory |
7.21 | 6.23 | 6.53 | 6.89 | |
Average Assets |
34.47 | 26.69 | 31.11 | 30.89 | |
Average Common Equity |
23.32 | 13.63 | 12.37 | 13.66 |
Columns are period end dates